ReproCell Inc
F:6RC

Watchlist Manager
ReproCell Inc Logo
ReproCell Inc
F:6RC
Watchlist
Price: 0.615 EUR 3.36% Market Closed
Market Cap: 57.4m EUR

EV/EBITDA
Enterprise Value to EBITDA

-18
Current
-26.1
Median
5.9
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-18
=
Enterprise Value
8.4B JPY
/
EBITDA
-464.5m JPY
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
JP
ReproCell Inc
F:6RC
Average EV/EBITDA: 38.6
Negative Multiple: -18
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 199 054.4 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 911.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.7
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -576.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
11%
1.6
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
168
N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-43.5
2-Years Forward
EV/EBITDA
-137.9
3-Years Forward
EV/EBITDA
N/A